Project Details


Breast Cancer 1000 Project 2014-2015 Breast Cancer 1000 Project 2014-2015 The LaBaer group is studying how changes in genetic context lead to profound differences in the behavior of cancer. Breast cancer is highly heterogeneous, with multiple well-defined disease subtypes, and significant variation even within those subtypes. A collaboration between driver genes (such as, oncogenes and tumor suppressor genes) with less commonly mutated genes (co-drivers) initiates and promotes cancer. It is difficult to distinguish less common co-driver genes from passenger" mutations that have no relation to cancer. A key driver gene in breast cancer is TP53, with mutations present in 35% of cases, especially basallike tumors. There are many different mutations in p53, and each may interact differently with the different codriver mutations. Successful treatment will likely require a combined approach that addresses both the p53 pathway as well as the co-driver pathways that collaborate with p53 to cause cancer. We are performing functional studies to investigate the interaction between different p53 mutations found in breast cancer and various co-driver mutations. To accomplish this, we are currently investigating the behavioral changes associated with these p53 mutations to understand how they contribute to the hallmarks of cancer such as proliferation, invasion, and 3D cell morphology. Our results indicate that different TP53 mutations result in distinct cellular programs and behaviors. Some mutants showed aggressive cellular phenotypes and correlated with worst clinical outcomes, whereas others were less aggressive and have better prognoses.
Effective start/end date10/1/149/30/15


  • Breast Cancer Research Foundation: $240,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.